查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1443368

降胆固醇药物市场，按药物类别、按疾病类型、按配销通路、按国家和地区划分 - 2024-2032 年行业分析、市场规模、市场份额和预测

Cholesterol-lowering Drug Market, By Drug class, By Disease type, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 288 Pages | 商品交期: 2-3个工作天内

价格

报告要点

2023年降胆固醇药物市场规模为1,840,087万美元，2024年至2032年复合CAGR为3.4%。

降胆固醇药物市场-市场动态

提高对高胆固醇不利影响的认识以推动市场需求

由于人们对高胆固醇不良影响的认识不断提高，全球降胆固醇药物市场正经历显着成长。这种成长促使製造商进行广泛的调查研究，以确定耐受性良好的药物，以改善患者的治疗结果。此外，该行业强劲的研发活动，以及用于开发新药的 bempedoic 酸的加入，都有助于市场的成长。迎合非他汀类药物使用者的新药物类别的出现正在推动市场成长。然而，他汀类药物使用者数量的不断增加以及各种指南对降血脂药采用的认可进一步推动了市场的扩张。胆固醇水平升高会增加中风和心肌梗塞的风险，而高胆固醇血症则与心血管疾病 (CVD) 以及慢性肾臟病和 2 型糖尿病等合併症的易感性增加有关。这些因素是市场成长的额外驱动力。 Bempedoic Acid、PCSK9抑制剂和其他药物等疗法的推出预计将有助于市场的持续扩张。

降胆固醇药物市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032 年）每年将以 3.4% 左右的CAGR成长

根据药物类别细分，预计他汀类药物将在 2023 年占据最大市场份额

根据疾病类型细分，2023年高胆固醇血症为主导类型

按地区划分，北美是 2023 年的主要收入来源

降胆固醇药物市场-細項分析：

全球降胆固醇药物市场根据药物类别、疾病类型、配销通路和地区进行细分。

市场依药物类别分为五大类：合併用药、PCSK9抑制剂、胆固醇吸收抑制剂、胆汁酸螯合剂和他汀类药物。他汀类药物占据了全球降胆固醇药物市场的最大份额，这主要是由于 Bempedoic Acid 和 PCSK9 抑制剂等有效疗法的推出。

市场依疾病类型分为四类：高胆固醇血症、心血管疾病、高血脂、其他。在降胆固醇药物市场的疾病类型中，高胆固醇血症是一个主要焦点。高胆固醇血症以血液中胆固醇水平升高为特征，由于其与心血管疾病密切相关，因此是降胆固醇药物的主要目标。作为动脉粥状硬化的关键因素，高胆固醇血症是心臟相关疾病的重要危险因子。因此，製药公司大力投资开发和行销药物，例如他汀类药物和 PCSK9 抑制剂，专门用于解决高胆固醇血症和降低心血管事件的风险。高胆固醇血症在全球的流行凸显了其在塑造降胆固醇药物开发模式和市场趋势的主导地位。

降胆固醇药物市场-地理洞察

从地理来看，该市场广泛分布于北美、拉丁美洲、欧洲、亚太地区以及中东和非洲地区。这些区域根据开展业务的国家进一步划分。

降胆固醇药物市场-竞争格局：

降胆固醇药物市场的公司正在策略性地引领心血管健康和个人化医疗不断发展的格局。正在进行的研究和开发工作重点是发现新的治疗标靶以及开发具有更高疗效和更少副作用的下一代降胆固醇药物。与医疗保健提供者、研究机构和监管机构的策略合作有助于进行临床试验并获得新药物配方的市场批准。此外，也进行教育活动和宣传活动，以强调胆固醇管理的重要性以及这些药物在预防心血管事件中的作用。随着市场转向个人化治疗方法，公司正在投资精准医疗策略，探索遗传因素，并利用创新技术根据个别患者的需求量身订做降胆固醇疗法。降胆固醇药物市场仍然是全球对抗心血管疾病和改善整体心臟健康努力不可或缺的一部分。

最近的发展：

2021 年，Inclisiran 获得 NHS 批准使用，临床试验证明其能够降低约 50% 的 LDL 胆固醇水平。据英国 NHS 称，以 Leqvio 品牌销售的 Inclisiran 有可能避免 55,000 例心臟病和中风，到 2031 年估计可挽救 30,000 人的生命。

目录

第一章：降胆固醇药物市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 按药物类别分類的降胆固醇药物市场片段
    • 按疾病类型分類的降胆固醇药物市场片段
    • 按配销通路分類的降胆固醇药物市场片段
    • 按国家/地区分類的降胆固醇药物市场摘要
    • 按地区分類的降胆固醇药物市场片段
  • 竞争洞察

第 3 章：降胆固醇药物主要市场趋势

  • 降胆固醇药物市场驱动因素
    • 市场驱动因素的影响分析
  • 降胆固醇药物市场限制
    • 市场限制影响分析
  • 降胆固醇药物市场机会
  • 降胆固醇药物市场未来趋势

第 4 章：降胆固醇药物工业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：降胆固醇药物市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：降胆固醇药物市场格局

  • 2023 年降胆固醇药物市占率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：降胆固醇药物市场 - 按药物类别

  • 概述
    • 按药品类别分類的细分市场份额分析
    • 组合药物
    • Pcsk9抑制剂
    • 胆固醇吸收抑制剂
    • 胆汁酸螯合剂
    • 他汀类药物

第 8 章：降胆固醇药物市场 - 按疾病类型

  • 概述
    • 按疾病类型分類的细分市场份额分析
    • 高胆固醇血症
    • 心血管疾病
    • 高血脂症
    • 其他的

第 9 章：降胆固醇药物市场 - 按配销通路

  • 概述
    • 按配销通路分類的细分市场份额分析
    • 医院药房
    • 网路药局
    • 零售药局
    • 其他的

第 10 章：降胆固醇药物市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美降胆固醇药物主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按药物类别）
    • 北美市场规模和预测（按疾病类型）
    • 北美市场规模和预测（按配销通路）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲降胆固醇药物主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按药物类别）
    • 欧洲市场规模与预测（按疾病类型）
    • 欧洲市场规模和预测（按配销通路）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区降胆固醇药物主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模和预测（按药物类别）
    • 亚太地区市场规模与预测（按疾病类型）
    • 亚太地区市场规模和预测（按配销通路）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲降胆固醇药物主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按药物类别）
    • 拉丁美洲市场规模与预测（按疾病类型）
    • 拉丁美洲市场规模和预测（按配销通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲降胆固醇药物主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按药物类别）
    • 中东和非洲市场规模及预测（按疾病类型）
    • 中东和非洲市场规模及预测（按配销通路）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 11 章：主要供应商分析 - 降胆固醇药物产业

  • 竞争仪表板
  • 公司简介
    • Daiichi Sankyo
    • Merck & Co., Inc.
    • AstraZeneca
    • Esperion Therapeutics and CJ Healthcare
    • Sanofi
    • Amgen, Inc.
    • Pfizer, Inc,
    • Merck & Co., Inc.
    • AbbVie, Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Takeda Pharmaceutical Company Limited
    • Novartis AG
    • GlaxoSmithKline plc.
    • Others

第 12 章：360 度分析师视角

第 13 章：附录

  • 研究方法论
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
Product Code: AVB2262

REPORT HIGHLIGHT

Cholesterol-lowering Drug Market size was valued at USD 18,400.87 Million in 2023, expanding at a CAGR of 3.4% from 2024 to 2032.

Cholesterol is categorized within the class of steroids, which are organic molecules and a type of lipids. It serves as a crucial structural component in the membranes of animal cells and is biosynthesized by all animal cells. The significance of cholesterol lies in its role in the biological synthesis of steroid hormones such as testosterone and estrogen, vitamin D, and bile acids. The primary sources of cholesterol production include poultry, meat, eggs, and dairy products. Elevated cholesterol levels can result from genetic diseases, obesity, an unhealthy diet, and various other medical conditions. The market for cholesterol-lowering drugs encompasses pharmaceuticals designed to decrease elevated cholesterol levels in the bloodstream, with a primary focus on reducing low-density lipoprotein (LDL) cholesterol. These drugs play a pivotal role in managing cardiovascular health by lowering the risk of atherosclerosis and related complications. As conditions like hypercholesterolemia and cardiovascular diseases become more prevalent globally, cholesterol-lowering drugs, such as statins, PCSK9 inhibitors, and bile acid sequestrants, are commonly prescribed to regulate cholesterol levels and mitigate the risk of heart-related conditions.

Cholesterol-lowering Drug Market- Market Dynamics

Increasing awareness of high cholesterol's adverse effects to propel market demand

The global Cholesterol-lowering Drug market is experiencing significant growth, driven by increasing awareness of high cholesterol's adverse effects. This growth has prompted manufacturers to conduct extensive investigational studies to identify well-tolerated drugs for improved patient outcomes. Furthermore, robust research and development activities in the sector, along with the incorporation of bempedoic acid for developing new drugs, contribute to the market's growth. The emergence of new drug classes catering to non-statin users is boosting market growth. However, the rising number of statin users and the endorsement of antihyperlipidemic adoption by various guidelines further propel market expansion. Elevated cholesterol levels increase the risks of stroke and myocardial infarction, while hypercholesterolemia is linked to increased vulnerability to cardiovascular diseases (CVD) and comorbidities like chronic kidney disease and type 2 diabetes. These factors act as additional drivers for market growth. The introduction of therapies such as bempedoic acid, PCSK9 inhibitors, and other drugs is expected to contribute to the market's continued expansion.

Cholesterol-lowering Drug Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 3.4% over the forecast period (2024-2032)

Based on drug class segmentation, statins was predicted to show maximum market share in the year 2023

Based on disease type segmentation, hypercholesterolemia was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Cholesterol-lowering Drug Market- Segmentation Analysis:

The Global Cholesterol-lowering Drug Market is segmented on the basis of Drug class, Disease type, Distribution Channel, and Region.

The market is divided into five categories based on drug class: combination drugs, PCSK9 inhibitors, cholesterol absorption inhibitors, bile acid sequestrants, and statins. The statins segment commands the largest portion of the global cholesterol-lowering drug market, primarily due to the introduction of effective therapies such as bempedoic acid and PCSK9 inhibitors.

The market is divided into four categories based on disease type: Hypercholesterolemia, Cardiovascular Diseases, Hyperlipidaemia, Others. Among the disease types in the cholesterol-lowering drug market, hypercholesterolemia stands out as a dominant focus. Hypercholesterolemia, characterized by elevated levels of cholesterol in the blood, is a primary target for cholesterol-lowering drugs due to its strong association with cardiovascular diseases. As a key contributor to atherosclerosis, hypercholesterolemia is a significant risk factor for heart-related conditions. Consequently, pharmaceutical companies are heavily invested in developing and marketing drugs, such as statins and PCSK9 inhibitors, specifically tailored to address hypercholesterolemia and mitigate the risk of cardiovascular events. The prevalence of hypercholesterolemia worldwide underscores its dominance in shaping the landscape of cholesterol-lowering drug development and market trends.

Cholesterol-lowering Drug Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Cholesterol-lowering Drug Market- Competitive Landscape:

Companies in the cholesterol-lowering drug market are strategically navigating the evolving landscape of cardiovascular health and personalized medicine. Ongoing research and development efforts focus on the discovery of novel therapeutic targets and the development of next-generation cholesterol-lowering drugs with improved efficacy and fewer side effects. Strategic collaborations with healthcare providers, research institutions, and regulatory bodies aid in conducting clinical trials and gaining market approvals for new drug formulations. Additionally, educational initiatives and awareness campaigns are undertaken to highlight the importance of cholesterol management and the role of these drugs in preventing cardiovascular events. As the market shifts towards personalized treatment approaches, companies are investing in precision medicine strategies, exploring genetic factors, and leveraging innovative technologies to tailor cholesterol-lowering therapies for individual patient needs. The cholesterol-lowering drug market remains integral to global efforts in combating cardiovascular diseases and improving overall heart health.

Recent Developments:

In 2021, Inclisiran received approval for NHS use following clinical trials that demonstrated its ability to reduce LDL cholesterol levels by approximately 50%. According to NHS England, Inclisiran, marketed under the brand name Leqvio, has the potential to avert 55,000 heart attacks and strokes, leading to an estimated 30,000 lives saved by the year 2031.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CHOLESTEROL-LOWERING DRUG MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Daiichi Sankyo

Merck & Co., Inc.

AstraZeneca

Esperion Therapeutics and CJ Healthcare

Sanofi

Amgen, Inc.

Pfizer, Inc,

Merck & Co., Inc.

AbbVie, Inc.

Sun Pharmaceutical Industries Ltd.

Takeda Pharmaceutical Company Limited

Novartis AG

GlaxoSmithKline plc.

Others

GLOBAL CHOLESTEROL-LOWERING DRUG MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Combination drugs
  • Pcsk9 inhibitors
  • Cholesterol absorption inhibitors
  • Bile acid sequestrants
  • Statins

GLOBAL CHOLESTEROL-LOWERING DRUG MARKET, BY DISEASE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Hypercholesterolemia
  • Cardiovascular Diseases
  • Hyperlipidaemia
  • Others

GLOBAL CHOLESTEROL-LOWERING DRUG MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Others

GLOBAL CHOLESTEROL-LOWERING DRUG MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Cholesterol-lowering Drug Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Cholesterol-lowering Drug Market Snippet by Drug class
    • 2.1.2. Cholesterol-lowering Drug Market Snippet by Disease type
    • 2.1.3. Cholesterol-lowering Drug Market Snippet by Distribution channel
    • 2.1.4. Cholesterol-lowering Drug Market Snippet by Country
    • 2.1.5. Cholesterol-lowering Drug Market Snippet by Region
  • 2.2. Competitive Insights

3. Cholesterol-lowering Drug Key Market Trends

  • 3.1. Cholesterol-lowering Drug Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Cholesterol-lowering Drug Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Cholesterol-lowering Drug Market Opportunities
  • 3.4. Cholesterol-lowering Drug Market Future Trends

4. Cholesterol-lowering Drug Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Cholesterol-lowering Drug Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Cholesterol-lowering Drug Market Landscape

  • 6.1. Cholesterol-lowering Drug Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Cholesterol-lowering Drug Market - By Drug class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug class, 2023 & 2032 (%)
    • 7.1.2. Combination drugs
    • 7.1.3. Pcsk9 inhibitors
    • 7.1.4. Cholesterol absorption inhibitors
    • 7.1.5. Bile acid sequestrants
    • 7.1.6. Statins

8. Cholesterol-lowering Drug Market - By Disease type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Disease type, 2023 & 2032 (%)
    • 8.1.2. Hypercholesterolemia
    • 8.1.3. Cardiovascular Diseases
    • 8.1.4. Hyperlipidaemia
    • 8.1.5. Others

9. Cholesterol-lowering Drug Market - By Distribution channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution channel, 2023 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Online Pharmacies
    • 9.1.4. Retail Pharmacies
    • 9.1.5. Others

10. Cholesterol-lowering Drug Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Cholesterol-lowering Drug Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Cholesterol-lowering Drug Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Cholesterol-lowering Drug Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Cholesterol-lowering Drug Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Cholesterol-lowering Drug Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug class, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Disease type, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Cholesterol-lowering Drug Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Daiichi Sankyo
    • 11.2.2. Merck & Co., Inc.
    • 11.2.3. AstraZeneca
    • 11.2.4. Esperion Therapeutics and CJ Healthcare
    • 11.2.5. Sanofi
    • 11.2.6. Amgen, Inc.
    • 11.2.7. Pfizer, Inc,
    • 11.2.8. Merck & Co., Inc.
    • 11.2.9. AbbVie, Inc.
    • 11.2.10. Sun Pharmaceutical Industries Ltd.
    • 11.2.11. Takeda Pharmaceutical Company Limited
    • 11.2.12. Novartis AG
    • 11.2.13. GlaxoSmithKline plc.
    • 11.2.14. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Cholesterol-lowering Drug Market: Drug class Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Drug class
  • TABLE Global Cholesterol-lowering Drug Market, by Drug class 2019-2032 (USD Million)
  • TABLE Cholesterol-lowering Drug Market: Disease type Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Disease type
  • TABLE Global Cholesterol-lowering Drug Market, by Disease type 2019-2032 (USD Million)
  • TABLE Cholesterol-lowering Drug Market: Distribution channel Snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution channel
  • TABLE Global Cholesterol-lowering Drug Market, by Distribution channel 2019-2032 (USD Million)
  • TABLE Cholesterol-lowering Drug Market: Regional snapshot (2023)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Cholesterol-lowering Drug Market, by Region 2019-2032 (USD Million)
  • TABLE North America Cholesterol-lowering Drug Market, by Country, 2019-2032 (USD Million)
  • TABLE North America Cholesterol-lowering Drug Market, by Drug class, 2019-2032 (USD Million)
  • TABLE North America Cholesterol-lowering Drug Market, by Disease type, 2019-2032 (USD Million)
  • TABLE North America Cholesterol-lowering Drug Market, by Distribution channel, 2019-2032 (USD Million)
  • TABLE Europe Cholesterol-lowering Drug Market, by Country, 2019-2032 (USD Million)
  • TABLE Europe Cholesterol-lowering Drug Market, by Drug class, 2019-2032 (USD Million)
  • TABLE Europe Cholesterol-lowering Drug Market, by Disease type, 2019-2032 (USD Million)
  • TABLE Europe Cholesterol-lowering Drug Market, by Distribution channel, 2019-2032 (USD Million)
  • TABLE Asia Pacific Cholesterol-lowering Drug Market, by Country, 2019-2032 (USD Million)
  • TABLE Asia Pacific Cholesterol-lowering Drug Market, by Drug class, 2019-2032 (USD Million)
  • TABLE Asia Pacific Cholesterol-lowering Drug Market, by Disease type, 2019-2032 (USD Million)
  • TABLE Asia Pacific Cholesterol-lowering Drug Market, by Distribution channel, 2019-2032 (USD Million)
  • TABLE Latin America Cholesterol-lowering Drug Market, by Country, 2019-2032 (USD Million)
  • TABLE Latin America Cholesterol-lowering Drug Market, by Drug class, 2019-2032 (USD Million)
  • TABLE Latin America Cholesterol-lowering Drug Market, by Disease type, 2019-2032 (USD Million)
  • TABLE Latin America Cholesterol-lowering Drug Market, by Distribution channel, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Cholesterol-lowering Drug Market, by Country, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Cholesterol-lowering Drug Market, by Drug class, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Cholesterol-lowering Drug Market, by Disease type, 2019-2032 (USD Million)
  • TABLE Middle East and Africa Cholesterol-lowering Drug Market, by Distribution channel, 2019-2032 (USD Million)